Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective, multi-center, randomized, sham-controlled clinical investigation designed to evaluate the safety and effectiveness of the Lacrima VR system in adult subjects with Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). Subjects will be randomized in a 1:1 ratio to receive either active Lacrima VR treatment or a sham device with reduced luminance. Effectiveness will be assessed primarily by change in Tear Break-Up Time (TBUT), and safety will be evaluated by the incidence of device-related adverse events.
Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD) are common ocular surface disorders associated with tear film instability, ocular discomfort, and impaired visual function. The Lacrima VR system is a non-invasive medical device that delivers controlled sequences of light pulses using virtual reality technology, intended to activate reflex pathways associated with lacrimal and meibomian gland function.
This randomized, evaluator-masked study compares the Lacrima VR system with a sham device that is identical in appearance but operates at substantially reduced luminance. Subjects will undergo four treatment sessions at two-week intervals, followed by follow-up visits at 4 and 10 weeks after the final treatment. Effectiveness will be assessed using objective measures (TBUT) and patient-reported outcomes (OSDI). Safety assessments will include monitoring of adverse events, intraocular pressure, visual acuity, and discomfort questionnaires.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active Lacrima VR | Experimental | Participants receive treatment using the Lacrima VR headset delivering controlled light pulse sequences at a luminance of approximately 125 cd/m². Four treatment sessions are administered at two-week intervals. |
|
| Sham Control | Placebo Comparator | Participants receive treatment using an identical Lacrima VR headset operating at reduced luminance (approximately 25 cd/m²). Four treatment sessions are administered at two-week intervals. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lacrima VR System | Device | This is a prospective, randomized, sham-controlled, evaluator-masked clinical investigation designed to evaluate the safety and effectiveness of the Lacrima VR system in adult subjects with Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). Eligible participants will be randomized in a 1:1 ratio to receive either active Lacrima VR treatment or a sham device with reduced luminance. The intervention consists of four non-invasive treatment sessions administered at two-week intervals using a virtual reality headset that delivers controlled sequences of light pulses. All participants will undergo standardized ophthalmic assessments and patient-reported outcome evaluations at baseline and at predefined follow-up visits conducted 4 and 10 weeks after the final treatment session. Safety will be assessed throughout the study by monitoring adverse events, discomfort, and changes in ocular parameters. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Tear Break-Up Time (TBUT) at 4 Weeks | Change from baseline to the 4-week follow-up in Tear Break-Up Time (TBUT) will be assessed as an objective measure of tear film stability. TBUT will be measured in seconds using fluorescein dye by a masked evaluator who is not involved in treatment administration. The outcome is defined as the change from baseline in TBUT at specified follow-up visits, with measurements averaged across repeated assessments per eye.ear Break-Up Time (TBUT), measured in seconds by a masked evaluator. | Baseline to 4 weeks after final treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Tear Break-Up Time (TBUT) at 10 Weeks | Tear Break-Up Time (TBUT) will be assessed as an objective measure of tear film stability. TBUT will be measured in seconds using fluorescein dye by a masked evaluator who is not involved in treatment administration. The outcome is defined as the change from baseline in TBUT at specified follow-up visits, with measurements averaged across repeated assessments per eye. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hila Kfir | Contact | 972-523313350 | hila.k@demaod-med.com | |
| Ronen Shavit | Contact | 972-522420798 | ronen.s@demaod-med.com |
| Name | Affiliation | Role |
|---|---|---|
| michael Mimouni, Prof - Ophthalmology | Rambam Campus medical center | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015352 | Dry Eye Syndromes |
| ID | Term |
|---|---|
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Parallel Assignment
Not provided
Not provided
This study is single-masked. Outcome assessors are masked to treatment allocation. Participants are randomized to receive either the active Lacrima VR system or a sham device that is identical in appearance but operates at a reduced luminance. The evaluator performing objective outcome assessments, including Tear Break-Up Time (TBUT), is not involved in treatment administration and is not exposed to treatment sessions. Study personnel responsible for device setup and treatment delivery are not masked.
|
| Baseline to 10 weeks after final treatment |
| Change From Baseline in Ocular Surface Disease Index (OSDI) | Patient-reported symptoms assessed using theThe Ocular Surface Disease Index (OSDI) will be used to evaluate patient-reported symptoms related to dry eye disease and their impact on visual function and quality of life. The OSDI is a validated 12-item questionnaire, with scores ranging from 0 to 100, where higher scores indicate greater symptom severity. The outcome is defined as the change from baseline in OSDI score at follow-up visits. validated OSDI questionnaire | Baseline to 4 weeks and 10 weeks after final treatment |
| Incidence of Device-Related Adverse Events | The incidence, nature, severity, and relationship to the investigational device of all adverse events will be assessed throughout the study. Adverse events will be collected from the first treatment session through the final follow-up visit and categorized as device-related or non-device-related. Serious adverse events and unanticipated adverse device effects will be recorded and reported according to applicable regulatory requirements. | Adverse events will be assessed from baseline (first treatment) and 10 weeks (±7 days) after their final treatment |
| Changes in Intraocular Pressure (IOP) | Intraocular Pressure (IOP) will be measured in millimeters of mercury (mmHg) using standard clinical tonometry. IOP assessments will be conducted at baseline and at follow-up visits to monitor ocular safety. The outcome is defined as the change from baseline in IOP values following treatment. | Baseline to 4 and 10 weeks after final treatment |
| Changes in Best Corrected Visual Acuity (BCVA) | Best Corrected Visual Acuity (BCVA) will be assessed using standardized visual acuity testing under best spectacle correction. BCVA measurements will be recorded at baseline and follow-up visits to evaluate any changes in visual function. The outcome is defined as the change from baseline in BCVA following treatment. | Baseline to 4 and 10 weeks after final treatment |